Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Cervarix in HIV Infected Females
NCT01031069Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2010
- Primary completion
- Jan 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 4 trial of Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen in human papillomavirus infection, sponsored by GSK. Started Oct 2010; status: completed.
02
Drugs
Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT01031069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031069.